Loading…
← CockpitCompetitor Analysis › BIM.PA bioMerieux SAOpen in the cockpit ↗

bioMerieux SABIM.PACompetitor analysis, valuation and peers

France · EUR·Health Care›Medical Specialties

French maker of in-vitro diagnostics instruments and reagents for clinical microbiology and infectious disease testing.

Momentum leader 97
Mkt cap
$11.8B
US dollars, full cap
Free float
32%
of shares outstanding
$/day
$15.5M
20-day average traded
Fwd P/E
20.2×
forward earnings
ROIC−WACC
+2.6 pp
WACC 8.5%
Hurdle
+3 pp
Req g minus delivered
Next earnings
100 days
26 Feb 2027
Close · EUR€90.75
1D+0.1%
1W-1.6%
1M+4.1%
3M+21.8%
6M+26.2%
YTD-17.7%
1Y-15.7%
ATR %2.2%
52w lowhigh21.8% off high

What bioMerieux does

French maker of in-vitro diagnostics instruments and reagents for clinical microbiology and infectious disease testing.

Places instruments in hospital and industrial labs, then earns on the tests run on them, so installed instruments drive repeat sales of reagents. Its 2014 purchase of BioFire added panels that test for many pathogens at once and made the US a main market. The Merieux family, through Institut Merieux, controls it.

Products and services

  • Clinical microbiology testing (VITEK)
  • Molecular diagnostics (BIOFIRE panels)
  • Industrial/food safety testing

Customers

  • Hospital labs, clinical diagnostics labs, food saf

Where it sits in the supply chain

  • Health Care
  • Diagnostics
  • In-vitro diagnostics (microbiology)

What could go right

  • Infectious disease/molecular testing demand
  • Panel menu expansion

What could go wrong

  • Post-pandemic testing demand normalization
  • Hospital lab capex budgets

Moat: narrow (installed base, switching costs, IP / patents). Placed diagnostic instrument base creates recurring reagent/consumable revenue.

Headquarters: Marcy-l'Etoile, France · Founded: 1963 · Employees: 15,078

Named competitors

bioMerieux at a glance

Size bioMerieux (BIM.PA) is a France Health Care company (Medical Specialties) with a market value of $11.8B, the 43rd largest of 206 France companies the cockpit tracks. Shares closed at €90.75 on 18 Nov 2026.

Performance Over six months the shares gained 26.2%, against +26.5% for the median peer and -2.1% for the France market (cap-weighted) — 11th highest of 21 in its peer set.

Growth Revenue fell 3.2% over the last twelve months (peer median +6.5%); the operating margin is 15.2% (peer median 15.0%).

Valuation It trades at 20.2× forward earnings against a peer median of 20.5× (11th cheapest of 21).

Price implies For today's price to make sense, revenue must grow about 9% a year for seven years (Req g). Recent delivered growth is +5%, so the hurdle is +3 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 2.6 points above its cost of capital (8.5% WACC).

Next results Next results expected around 26 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012021 May 202621 Aug 202618 Nov 2026Peer median 127BIM.PA 124
Six months, rebased to 100: bioMerieux against the median of its 20 peers (local-currency closes).

bioMerieux financials

Reported figures in EUR; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue€3.99B€4.07B€3.98B€3.67B€3.59B
Revenue growth—+2%+8%+2%—
Gross profit€2.21B€2.27B€2.18B€2.02B€1.96B
EBITDA€919M€973M€893M€795M€817M
Net income€463M€398M€432M€358M€452M
Free cash flow€586M€453M€322M€107M€188M
Capital expenditure€322M€335M€346M€338M€287M
Total debtn/a€461M€491M€519M€505M

Quarterly statements and history in the cockpit →

bioMerieux competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+20%+40%+60%0%+10%ALGNCOOSNPEN7733AVTRDEMANTQGENBAXLENSKARTBIOGKOSPODDBRKR688271GMEDCOLO-B7701RVTY6869BIM.PA6-month return →1-month return →
Up and to the right = strong over both horizons. bioMerieux is the large dot.

Fundamentals: revenue growth against valuation

0%+10%+20%+30%50×100×ALGNCOOPEN7733AVTRDEMANTQGENLENSKARTBIOGKOSPODDBRKR688271GMED6869BIM.PARevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. bioMerieux is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%ALGNCOOSNPEN7733AVTRDEMANTQGENBAXLENSKARTBIOPODDBRKRGMEDCOLO-B7701RVTYBIM.PAGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. bioMerieux is the large dot.

bioMerieux competitors and peer comparison

Head to head with its named competitors (BIM.PA vs ABT vs BDX vs TMO)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
bioMerieux BIM.PA$11.8B+26%-3%15%20.2×8.6%
Abbott Laboratories ABT$181B+18%+10%14%17.9×16.5%
Becton Dickinson BDX$58.9B+48%-7%16%16.3×-1.6%
Thermo Fisher Scientific TMO$257B+53%+8%19%25.7×21.3%

How bioMerieux compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

bioMerieux against its 20 peers (data as of 18 Nov 2026)
MeasureBIM.PAPeer medianRank in peer set
1-month return+4.1%+5.0%10th lowest of 21
6-month return+26.2%+26.5%11th highest of 21
Distance from 52-week high-21.8%-12.4%5th lowest of 21
Revenue growth (TTM)-3.2%+6.5%lowest of 21
Operating margin15.2%15.0%11th highest of 21
Forward P/E20.2×20.5×11th cheapest of 21
Growth the price implies (Req g, 7 yrs)8.6%10.8%7th least demanding of 19
Growth delivered (Del g)+5.5%+9.0%6th lowest of 19
Hurdle (Req g minus delivered)+3.1 pp+4.2 pp10th least demanding of 19
ROIC minus cost of capital+2.6 pp+2.3 pp9th highest of 21
EV / EBITDA11.4×13.4×7th cheapest of 19
Net debt / EBITDA-0.3×0.9×5th least indebted of 19

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
bioMerieux BIM.PAFrance$11.8B+26%-3%15%20.2×8.6%+5.5%
Align Technology ALGNUnited States$11.6B0%+4%19%13.8×13.1%+10.3%
Cooper Companies (The) COOUnited States$11.6B-2%+5%19%13.4×9.4%+11.0%
Smith & Nephew SN..LUnited Kingdom$12.6B+1%+2%17%14.2×11.1%+5.6%
Penumbra PENUnited States$12.6B-2%+17%12%55.7×30.7%+20.2%
Olympus 7733.TJapan$12.7B+5%+9%18%18.7×-6.5%+6.7%
Avantor AVTRUnited States$10.4B+95%+1%8%17.5×16.4%+0.5%
Demant A/S DEMANT.CODenmark$10.4B+39%+10%18%23.2×5.8%+9.8%
Qiagen QGENUnited States$10.2B+41%+2%25%19.5×8.6%+2.2%
Baxter International BAXUnited States$13.5B+39%+5%6%12.7×13.4%-0.7%
Lenskart Solutions LENSKART.NSIndia$13.6B+49%+35%10%137.7×53.2%+33.5%
Bio-Rad Laboratories BIOUnited States$10.1B+29%+1%9%34.6×26.0%+0.3%
Glaukos GKOSUnited States$13.8B+62%+47%-9%161.5×n/an/a
Insulet PODDUnited States$9.71B-11%+26%18%18.6×10.6%+24.5%
Bruker BRKRUnited States$9.66B+43%+2%10%27.0×25.4%+11.6%
Shanghai United Imaging Healthcare 688271.SSChina$14.4B+4%+27%9%45.7×n/an/a
Globus Medical GMEDUnited States$9.34B-16%+13%23%13.7×4.6%+30.1%
Coloplast A/S COLO-B.CODenmark$16.6B+24%+4%25%20.0×-2.1%+8.3%
Shimadzu 7701.TJapan$8.14B+24%+8%14%21.0×8.3%+7.3%
Revvity RVTYUnited States$17.0B+61%+5%16%26.2×26.4%-5.5%
Sysmex 6869.TJapan$8.06B+58%+8%13%32.0×4.4%+10.4%

Questions

Who are bioMerieux's main competitors?
Named competitors: Roche Diagnostics (private or unlisted), Abbott Laboratories (ABT), Becton Dickinson (BDX), Thermo Fisher Scientific (TMO). The cockpit's measured peer set (industry) also includes Align Technology (ALGN), Cooper Companies (The) (COO), Smith & Nephew (SN..L), Penumbra (PEN), Olympus (7733.T), Avantor (AVTR).
Is bioMerieux expensive compared with its peers?
On forward p/e it trades at 20.2× against a peer median of 20.5×, 11th cheapest of 21 in its peer set. For today's price to make sense, revenue must grow about 9% a year for seven years (Req g). Recent delivered growth is +5%, so the hurdle is +3 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has bioMerieux stock performed?
Over six months to 18 Nov 2026 the shares returned +26.2% against +26.5% for the median peer; over one year -15.7%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.